These results imply that these PTMs, including the novel and Alzheimer's disease–specific succinylation of tau K311, may influence both the physiological and pathological interactions of tau and thus represent targets for therapeutic intervention. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.